Building an Integrated Management Model from Diagnosis to Treatment

Daewoong Pharmaceutical is partnering with the medical imaging artificial intelligence (AI) company Promedius to establish a new patient management model that enables the early identification of osteoporosis risk groups using chest X-rays, and connects patients to diagnosis and treatment.


On August 27, Daewoong Pharmaceutical announced that it had signed a contract with Promedius for the domestic sales, distribution, and joint promotion of the chest X-ray-based AI osteoporosis risk screening solution "OsteoSignal."


Changjae Lee, CEO of Daewoong Pharmaceutical (left), and Hyunjin Bae, CEO of Promedius, are signing a contract for the domestic sales, distribution, and joint promotion of the AI-based osteoporosis risk screening solution based on chest X-rays, "OsteoSignal." Daewoong Pharmaceutical

Changjae Lee, CEO of Daewoong Pharmaceutical (left), and Hyunjin Bae, CEO of Promedius, are signing a contract for the domestic sales, distribution, and joint promotion of the AI-based osteoporosis risk screening solution based on chest X-rays, "OsteoSignal." Daewoong Pharmaceutical

View original image

Through this agreement, the two companies will collaborate to expand the supply of OsteoSignal to healthcare institutions across Korea and to jointly promote the solution. Daewoong Pharmaceutical plans to leverage its nationwide healthcare network to drive market expansion, while Promedius will support the solution’s adoption in medical settings with its medical imaging AI technology and product competitiveness.


OsteoSignal is a screening solution that uses AI to analyze chest X-ray images taken during health checkups or general medical care, providing an assessment of osteoporosis risk. It helps identify osteoporosis risk groups by utilizing existing chest X-ray images without any additional imaging, and assists in finding patients who require further testing, such as bone density examinations.


The two companies aim to expand the adoption of OsteoSignal in medical sites where chest X-ray imaging is routinely performed, such as health screening centers and hospitals or clinics.



Changjae Lee, CEO of Daewoong Pharmaceutical, stated, "Through OsteoSignal, we plan not only to identify osteoporosis risk groups from conventional chest X-rays, but also connect patients to bone density testing and diagnosis. At the treatment stage, by utilizing Daewoong Pharmaceutical's therapeutic options, we will establish an integrated management model for osteoporosis that connects early screening to diagnosis and treatment."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing